GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Cyclically Adjusted Price-to-FCF

Karolinska Development AB (Karolinska Development AB) Cyclically Adjusted Price-to-FCF : (As of May. 20, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Karolinska Development AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Karolinska Development AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Cyclically Adjusted Price-to-FCF Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Karolinska Development AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Karolinska Development AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's Cyclically Adjusted Price-to-FCF falls into.



Karolinska Development AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Karolinska Development AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Karolinska Development AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.002/132.2054*132.2054
=-0.002

Current CPI (Mar. 2024) = 132.2054.

Karolinska Development AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.034 100.432 0.045
201409 -0.056 100.161 -0.074
201412 -0.193 100.225 -0.255
201503 -0.415 99.950 -0.549
201506 -0.054 99.995 -0.071
201509 -0.109 100.228 -0.144
201512 -0.060 100.276 -0.079
201603 -0.019 100.751 -0.025
201606 0.002 101.019 0.003
201609 0.016 101.138 0.021
201612 -0.014 102.022 -0.018
201703 0.010 102.022 0.013
201706 -0.004 102.752 -0.005
201709 -0.003 103.279 -0.004
201712 -0.054 103.793 -0.069
201803 -0.021 103.962 -0.027
201806 -0.015 104.875 -0.019
201809 -0.008 105.679 -0.010
201812 0.061 105.912 0.076
201903 -0.010 105.886 -0.012
201906 -0.014 106.742 -0.017
201909 -0.042 107.214 -0.052
201912 0.036 107.766 0.044
202003 -0.019 106.563 -0.024
202006 -0.008 107.498 -0.010
202009 -0.005 107.635 -0.006
202012 0.016 108.296 0.020
202103 -0.006 108.360 -0.007
202106 -0.004 108.928 -0.005
202109 0.024 110.338 0.029
202112 -0.003 112.486 -0.004
202203 -0.007 114.825 -0.008
202206 -0.002 118.384 -0.002
202209 -0.002 122.296 -0.002
202212 -0.002 126.365 -0.002
202303 -0.003 127.042 -0.003
202306 -0.002 129.407 -0.002
202309 -0.002 130.224 -0.002
202312 -0.002 131.912 -0.002
202403 -0.002 132.205 -0.002

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Karolinska Development AB  (OTCPK:KDEVF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Karolinska Development AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (Karolinska Development AB) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.